Patients with COVID-2019. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: 15 patients with COVID-19 in addition to a standard regimen will receive 30 mg intravenous infusion edaravone (C10H10N2O, Zist Daroo Co., Iran) every 12 hours for 1
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with COVID-19-induced pneumonia confirmed with Polymerase chain reaction (PCR) Patients with COVID-19-induced pneumonia confirmed with chest CT scan results 18 to 80 years old Patients with acute respiratory distress syndrome (ARDS) according to Berlin ARDS criteria
Exclusion criteria
Exclusion criteria: Patients who are participating in other drug clinical trials Pregnant or lactating women Patient with drug allergy Patients on mechanical ventilation Patients with expected survival duration< 24 h
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization days. Timepoint: At baseline and discharge time. Method of measurement: Counting the days.;Need for mechanical ventilation. Timepoint: From baseline to discharge time. Method of measurement: Observation and documents.;Condition of discharge (death or recovery). Timepoint: End of hospitalization. Method of measurement: Observation and documents. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMojtaba Varshochi
Tabriz University of Medical Sciences
Outcome results
None listed